Related Experiment Video
Updated: Jul 20, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial
Christopher W J McChalicher1, Mary-Jane Lombardo1, Sahil Khanna2
1Seres Therapeutics, Cambridge, Massachusetts, USA.
Background:
Although fecal microbiota transplant has been used to prevent recurrent Clostridioides difficile infection (rCDI), documented pathogen transmissions highlight inherent safety risks of minimally processed stool. We describe manufacturing processes for fecal microbiota spores, live (VOWST; VOS, formerly SER-109), a microbiota-based oral therapeutic of Firmicutes spores.
Methods:
Bacterial inactivation kill curves were obtained after ethanol exposure for 4 model organisms spiked into process intermediates.
Results:
Bacterial log reduction factors ranged from 6.5 log10 to 7.4 log10 and lysis of spiked organisms occurred rapidly within 30 seconds.
Conclusions:
These experiments demonstrate substantial and rapid inactivation of representative organisms, supporting the potential benefit of VOS manufacturing processes to mitigate risk.
Insights
Manufacturing fecal microbiota spores live (VOS) involves rapid bacterial inactivation, significantly reducing safety risks associated with fecal microbiota transplants for recurrent Clostridioides difficile infection.
Area of Science:
- Microbiology
- Gastroenterology
- Pharmaceutical Manufacturing
Background:
- Fecal microbiota transplant (FMT) prevents recurrent Clostridioides difficile infection (rCDI).
- Minimally processed stool poses safety risks due to potential pathogen transmission.
- Fecal microbiota spores, live (VOS) is an oral therapeutic derived from Firmicutes spores.
Purpose of the Study:
- To describe the manufacturing process for VOS.
- To evaluate the efficacy of VOS manufacturing in inactivating bacteria.
- To support the safety profile of VOS for rCDI treatment.
Main Methods:
- Bacterial inactivation kill curves were generated.
- Ethanol exposure was used to treat 4 model organisms in process intermediates.
- Rapid lysis and log reduction factors were measured.
Main Results:
- Bacterial log reduction factors ranged from 6.5 to 7.4 log10.
- Rapid lysis of spiked organisms occurred within 30 seconds.
- Demonstrated substantial and rapid inactivation of representative organisms.
Conclusions:
- VOS manufacturing processes significantly reduce bacterial contamination risks.
- The described methods support the safety of VOS as a therapeutic for rCDI.
- Rapid and substantial bacterial inactivation is a key benefit of the VOS manufacturing process.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Key Techniques in Microbiology
Need for Obtaining Pure Cultures

